GCS-100 additional clinical trial site

GlycoGenesys, Inc. today announced it has initiated Roswell Park Cancer Institute, (RPCI) Buffalo, New York as a clinical site for its Phase I/II dose escalation trial in patients with multiple myeloma. The trial is designed to evaluate the safety and efficacy of the Company's drug candidate, GCS-100. RPCI was the first cancer research center in the nation and is a National Cancer Institute designated comprehensive cancer center. The Principal Investigator is Asher A. Chanan-Khan, M.D. Dr. Chanan-Khan's research interests include novel therapies for multiple myeloma and chronic lymphocytic leukemia.

Dr. Chanan-Khan has participated in several important clinical studies in multiple myeloma, including the trials that led to regulatory approval of Velcade® marketed by Millennium Pharmaceuticals and Johnson and Johnson, as well as studies evaluating Celgene's Revlimid ® in patients with CLL.

The trial was designed with the assistance of Dr. Paul Richardson and Dr. Kenneth Anderson at the Dana-Farber Cancer Institute, based upon pre-clinical work conducted in Dr. Anderson's laboratory and recently published in Cancer Research 2005; 65:(18). This research shows that GCS-100:

• Induces cell death in multiple myeloma cells without significant toxicity against normal white blood cells;
• Directly targets multiple myeloma cells while in the presence of protective bone marrow cells;
• Triggers cell death in multiple myeloma cells resistant to commonly used anti-cancer agents including dexamethasone, melphalan, doxorubicin, and Velcade®; and
• Has additive and/or synergistic effect when combined with caspase-activating agents such as dexamethasone.